Posted by Michael Wonder on 13 Mar 2021
ICER publishes evidence report on therapies for lupus nephritis
12 March 2021 - The evidence suggests belimumab and voclosporin represent important new treatment options for lupus nephritis; there is substantial uncertainty regarding long-term use and outcomes, but at estimated net prices, both drugs appear priced in alignment with ICER’s recommended health-benefit price benchmark ranges.
The ICER today released an Evidence Report assessing the comparative clinical effectiveness and value of belimumab (Benlysta, GlaxoSmithKline) and voclosporin (Lupkynis, Aurinia) for the treatment of lupus nephritis. The FDA approved belimumab on 17 December 2020 and voclosporin on 22 January 2021.
